Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone

American Psychiatric Association, 1994 Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie, 1981 Barnes, 1989, A rating scale for drug-induced akathisia, Br J Psychiatry, 154, 672, 10.1192/bjp.154.5.672 Bersani, 1990, 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: A double-blind comparison with adrine and placebo, Clin Neuropharmacol, 13, 500, 10.1097/00002826-199012000-00003 Broich, 1993, Darstellung von Dopamin D2-Rezeptoren mittels J-IBZM-SPECT bei schizophrenen Patienten, 511 Brücke, 1991, Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatric disorders, J Cereb Blood Flow Metab, 11, 220, 10.1038/jcbfm.1991.53 Brücke, 1991, Dopamine receptor imaging with SPECT: A tool in extrapyramidal disorders and in vivo assay for the measurement of receptor blockade by neuroleptic treatment (Abstract), J Cereb Blood Flow Metab, 11, 877 Brücke, 1992, Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics, Lancet, 339, 497, 10.1016/0140-6736(92)91108-K Busatto, 1995, Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — An 123I-IBZM single photon emission tomography (SPET) study, Psychopharmacology, 117, 55, 10.1007/BF02245098 Farde, 1992, Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine, Arch Gen Psychiatry, 49, 538, 10.1001/archpsyc.1992.01820070032005 Farde, 1989, D1- and D2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics, Psychopharmacology, 99, 28, 10.1007/BF00442555 Grünwald, 1993, IBZM SPECT in psychiatric diseases Harasko-van der Meer, 1993, Two cases of long term dopamine D2 receptor blockade after depot neuroleptics, J Neural Transm, 94, 217, 10.1007/BF01277026 Hicks, 1990, The effect of serotonergic agents on haloperidol-induced catalepsy, Life Sci, 47, 1609, 10.1016/0024-3205(90)90365-X Janssen, 1988, Pharmacology of risperidone, a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties, J Pharmacol Exp Ther, 244, 685 Kay, 1987, The Positive and Negative Symptome Scale (PANSS) for Schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 Kerwin, 1993, Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone, Br J Psychiatry, 163, 833, 10.1192/bjp.163.6.833 McEvoy, 1994, Efficacy of risperidone on positive features of schizophrenia, J Clin Psychiatry, 55, 18 Nyberg, 1993, 5-HT2 and D2 dopamine receptor occupancy in the living human brain, Psychopharmacology, 110, 265, 10.1007/BF02251280 Owens, 1994, Extrapyramidal side effects and tolerability of risperidone: A review, J Clin Psychiatry, 55, 29 Scherer, 1994, Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics, Biol Psychiatry, 36, 627, 10.1016/0006-3223(94)90076-0 Schooler, 1994, Negative symptoms in schizophrenia: Assessment of the effect of risperidone, J Clin Psychiatry, 55, 22 Seibyl, 1992, Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine 123-IBZM, J Nucl Med, 33, 1964 Simpson, 1970, A rating scale for extrapyramidal side effects, Acta Psychiatr Scand, 212, 11, 10.1111/j.1600-0447.1970.tb02066.x Wojcik, 1980, Prevalence of tardive dyskinesia in an outpatient population, Compr Psychiatry, 21, 370, 10.1016/0010-440X(80)90018-8